Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | FDPS | P14324 | 5/20 | 0.60 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.59 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1234755 | 0.82 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL27564027 | 0.82 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL11806774 | 0.81 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL8630648 | 0.80 | FDPS (0.63) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL7383822 | 0.78 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL8058455 | 0.78 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL7823617 | 0.77 | VNN1 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL7823614 | 0.77 | VNN1 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL6427877 | 0.77 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL7861665 | 0.77 | FDPS (0.59) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444670-B2 | ENZYME INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES; ANTI-DIABETIC AGENTS; TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH OBESITY, GLUCOSE INTOLERANCE, DIABETES MELLITUS, HYPERTENSION AND ISCHEMIC DISEASES OF VESSELS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-6340676-B2 | ANTIBIABETIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-01-22 | — | — | US | disclosed |
| US-20020002187-A1 | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia | WYETH | 2002-01-03 | — | — | US | disclosed |
| US-20010020037-A1 | 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-09-06 | — | — | US | disclosed |
| US-6281238-B1 | USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA. | AMERICAN HOME PRODUCTS CORPORATION | 2001-08-28 | — | — | US | disclosed |
| EP-1077969-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1077970-A1 | 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6110962-A | FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-6057316-A | 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-6001867-A | HYPOGLYCEMIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999061435-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999058521-A1 | 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020037-A1 | 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes | INSR, IRS1, IGF1R | CYP1A2 195/4885CYP3A4 374/4885CYP2C9 256/4885 |
| US-20020002187-A1 | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia | IRS1, INSR, GPR119 | CYP1A2 450/4885CYP3A4 622/4885CYP2C9 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.